Hemogenyx Pharmaceuticals (LON:HEMO) Reaches New 12-Month Low – Here’s What Happened

Hemogenyx Pharmaceuticals Plc (LON:HEMO) reached a new 52-week low during mid-day trading on Tuesday . The company traded as low as GBX 175 ($2.27) and last traded at GBX 180.30 ($2.34), with a volume of 39831 shares traded. The stock had previously closed at GBX 184.75 ($2.40).

Hemogenyx Pharmaceuticals Trading Down 2.4 %

The business’s 50-day simple moving average is GBX 334.59 and its 200-day simple moving average is GBX 161.20. The company has a market cap of £6.43 million, a PE ratio of -922.33 and a beta of 3.14. The company has a current ratio of 4.38, a quick ratio of 6.72 and a debt-to-equity ratio of 90.87.

Hemogenyx Pharmaceuticals Company Profile

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.